Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NIH CONTRACEPTIVE DEVELOPMENT INITIATIVE PLANNED FOR FY 1986

Executive Summary

NIH CONTRACEPTIVE DEVELOPMENT INITIATIVE PLANNED FOR FY 1986 would be funded at $3.35 mil., National Institute of Child Health and Human Development Acting Director Duane Alexander told a March 27 hearing before the House Commerce/Health Subcmte. The initiative would "take advantage of some of the discoveries that are coming in from our basic reproductive sciences research programs that hold great promise for new types of contraception that will be applicable to different segments and ages of the population," Alexander said. NIH contraceptive development grant funding increased from $5.05 mil. in FY 1984 to $7.7 mil. in FY 1985, Alexander said, while funding for contraceptive evaluation increased from $2.5 mil in FY 1984 to $3.45 mil. in FY 1985. Subcmte. Chairman Waxman (D-Calif.) convened the hearing to receive testimony on reauthorization of the Public Health Service Act Title X family planning service program. In FY 1984, NIH "planned to spend over $11 mil." on contraceptive research, "but ended up spending almost 40% less than that," Waxman asserted. This was the "same year" that the congressional Office of Technology Assessment recommended that the agency spend "an additional $20 mil. on contraceptive development," he added.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

Latest Headlines
See All
UsernamePublicRestriction

Register

PS008174

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel